AI assistant
Sending…
ANAVEX LIFE SCIENCES CORP. — Director's Dealing 2024
Dec 24, 2024
32464_dirs_2024-12-23_5c810ba9-8d7b-4c64-afa5-48bbbd16de22.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ANAVEX LIFE SCIENCES CORP. (AVXL)
CIK: 0001314052
Period of Report: 2024-12-19
Reporting Person: Boenisch Sandra (PFO & Treasurer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-12-19 | Stock Option (Right to Buy) | $5.36 | A | 12500 | Acquired | 2034-02-20 | Common Stock (12500) | Direct |
Footnotes
F1: On February 20, 2024, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was regulatory submission of AD-004 for Alzheimer's disease (US or EU). The performance criteria for this milestone was met with the acceptance of the MAA filing by the EMA, resulting in vesting of the option as to 12,500 shares.
More from ANAVEX LIFE SCIENCES CORP.
Regulatory Filings
2026
May 22
Regulatory Filings
2026
May 15
Regulatory Filings
2026
May 6
Regulatory Filings
2026
Feb 25
Interim / Quarterly Report
2026
Feb 9
Regulatory Filings
2026
Feb 9
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9
Annual Report
2025
Nov 25
Regulatory Filings
2025
Nov 25